Bellone, M., Sabinot, A., D’Arpino, A., Omodeo Salè, E., Ghislieri, D. and Pradelli, L. 2024. A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy. Global and Regional Health Technology Assessment. 11, 1 (Dec. 2024), 239–247. DOI:https://doi.org/10.33393/grhta.2024.3170.